Differential response of SHH-expressing adult medulloblastomas to the sonic hedgehog inhibitor vismodegib: whole-genome analysis

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Medulloblastoma is an aggressive primitive neuroectodermal tumor of the cerebellum that is more common in children than in adults. In the past decade, advances in understanding the molecular drivers of medulloblastoma have identified four molecular subgroups defined by experimental gene expression profiles: the WNT pathway, sonic hedgehog (SHH) pathway, and subgroups 3 and 4 (non-SHH/WNT).  Medulloblastoma of adults belong primarily to the SHH category. Vismodegib, an SHH-pathway inhibitor, FDA-approved in 2012 for treatment of basal cell carcinoma, has been used successfully in the setting of chemorefractory medulloblastoma, but not as a first-line therapy. In 2016, we reported a case of an adult patient with a sustained response of an unresectable multifocal form of adult medulloblastoma to vismodegib. Molecular analysis in that case revealed mutations in TP53 and a cytogenetic abnormality, i17q, that is prevalent and most often associated with subgroup 4 rather than the SHH-activated form of medulloblastoma. Here, we report further whole-genome analysis of that patient (designated Patient A) as well as an additional adult patient (Patient B) whose tumor harbored the SHH molecular subgroup but which was unresponsive to visgmodegib therapy. Comparison of these disparate responses highlights the challenges to tailoring SHH-targeted treatment in individual patients with adult medulloblastoma.

Original languageEnglish (US)
Pages (from-to)1398-1402
Number of pages5
JournalCancer Biology and Therapy
Volume20
Issue number11
DOIs
StatePublished - Nov 2 2019

Bibliographical note

Funding Information:
The authors wish to thank Patient A for providing blood specimens for research purposes, as well as both patients and their families, and Sebastian Brabetz, Martin Sill and the DKFZ sequencing core facility in Heidelberg for their help with the analyses. EL received funding from Minnesota Masonic Charities, The Litman Family Fund for Cancer Research, and Courage and a Cure.

Funding Information:
This work was supported by the Minnesota Masonic Charities [n/a]; Courage and a Cure [n/a]; Litman Family Fund for Cancer Research [n/a]; the Mu Sigma Chapter of the Phi Gamma Delta Fraternity; the University of Minnesota. The authors wish to thank Patient A for providing blood specimens for research purposes, as well as both patients and their families, and Sebastian Brabetz, Martin Sill and the DKFZ sequencing core facility in Heidelberg for their help with the analyses. EL received funding from Minnesota Masonic Charities, The Litman Family Fund for Cancer Research, and Courage and a Cure.

Publisher Copyright:
© 2019, © 2019 Taylor & Francis Group, LLC.

Keywords

  • Medulloblastoma
  • sonic hedgehog
  • targeted therapy
  • vismodegib

Fingerprint Dive into the research topics of 'Differential response of SHH-expressing adult medulloblastomas to the sonic hedgehog inhibitor vismodegib: whole-genome analysis'. Together they form a unique fingerprint.

Cite this